首页> 外文期刊>Chinese Medical Journal >Experimental study on a novel compound extracted from Traditional Chinese Medicine for treatment of alveolar echinococcosis
【24h】

Experimental study on a novel compound extracted from Traditional Chinese Medicine for treatment of alveolar echinococcosis

机译:一种中药提取的新型化合物治疗肺泡棘球co病的实验研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To evaluate the efficacy of a novel compound derived from Traditional Chinese Medicine (TCM) for treatment of alveolar echinococcosis in the Kuming mouse. Methods The compound was extracted from TCM by serial procedures including amalgamation of TCM drugs, boiling in a beaker, cold condensation using a reflux instrument, evaporation by mild heating and finally, formation of a deep brown powder. An animal model of alveolar echinococcosis was established concurrently. A bit of alveococcus tissue derived from alveolar echinococcosis in the mouse was transplanted into the peritoneal cavity of the musculus of a Kuming mouse. The duration of infection after inoculation was classified as either 1 week or 10 weeks; the animals were again divided into treated groups and control groups. Estimation of the alveococcus inhibitory rate and electron microscopic observation served as the main methods for assessment of efficacy. The infected mice in the treated groups were intra-gastrically administered once per day with the TCM extractive powder at doses of 20 mg · kg~(-1) for three months continuously. All the animals were sacrificed and examined half a month after the end of TCM treatment. Results Total wet weight of alveococcus collected from the 9 mice in the treated group after one week of infection was 37.8g (x +- s, 4.196+-2.090 g), which was markedly lower than the amount collected from 10 mice of the control group (121.3 g, x +- s, 12.1 +- 4.3 g). Therefore, the inhibitory rate of the alveococcus was 65.7% (P < 0.01). Similarly, the total wet weight of alveococcus from 7 mice of the treated group after 10 weeks of infection was 4.3g (x +- s, 0.62+-1.21 g), which was much lower than the amount collected from 6 mice of the control group (17.85g, x +- s, 2.93 +- 3.28 g). The inhibitory rate of alveococcus was 80.6% ( P < 0.01) . Furthermore, the ultrastructural appearances of alveococcus showed obvious differences between the two groups. Conclusion TCM extractive powder for treatment of murine alveococcosis is considered to be a hopeful anti-echinococcus compound it is a topic for further study.
机译:目的评价中药(TCM)衍生的新型化合物治疗库明小鼠肺泡棘球co病的疗效。方法通过以下方法从中药中提取该化合物:将中药合并,在烧杯中煮沸,用回流仪冷冷凝,通过温和加热蒸发,最后形成深棕色粉末。同时建立了肺泡棘球co病的动物模型。将小鼠中的一部分源自肺泡棘球菌病的肺炎球菌组织移植到Kuming小鼠的小肠的腹膜腔中。接种后的感染持续时间分为1周或10周。将动物再次分为治疗组和对照组。肺泡球菌抑制率的估计和电子显微镜观察是评估疗效的主要方法。每天一次以20 mg·kg〜(-1)的剂量将中药提取粉灌胃给予治疗组的感染小鼠,连续三个月。中药治疗结束后半个月,处死所有动物并检查。结果感染1周后,从治疗组的9只小鼠收集的肺炎球菌总湿重为37.8g(x +-s,4.196 + -2.090 g),明显低于从对照组的10只小鼠收集的量组(121.3g,x±s,12.1±4.3g)。因此,肺泡球菌的抑制率为65.7%(P <0.01)。同样,感染10周后,治疗组的7只小鼠的肺炎球菌总湿重为4.3g(x +-s,0.62 + -1.21 g),远低于从对照组的6只小鼠收集的量组(17.85g,x±s,2.93±3.28g)。肺泡球菌的抑制率为80.6%(P <0.01)。此外,肺炎球菌的超微结构表现出两组之间的明显差异。结论中药提取物治疗鼠肺炎球菌病被认为是一种有希望的抗链球菌复合物,值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号